Antimicrobial activity of the leprostatic drug 3-(p-chloranilino)-10-(p-chlorphenyl-2,10-dihydro-2-(isopropylimino)-phenazine (G 30'320, B. 663).
D000818:Animals; D000995:Antitubercular Agents / Q000627:therapeutic use; D001228:Aspergillosis / Q000188:drug therapy; D002177:Candidiasis / Q000188:drug therapy; D002738:Chloroquine / Q000494:pharmacology*; D006224:Cricetinae; D004195:Disease Models, Animal; D004352:Drug Resistance, Microbial; D004357:Drug Synergism; D004927:Escherichia coli Infections / Q000188:drug therapy; D005260:Female; D007538:Isoniazid / Q000627:therapeutic use*; D007710:Klebsiella Infections / Q000188:drug therapy; D007918:Leprosy / Q000188:drug therapy; D008088:Listeriosis / Q000188:drug therapy; D008288:Malaria / Q000188:drug therapy; D051379:Mice; D009164:Mycobacterium Infections / Q000188:drug therapy; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D009181:Mycoses / Q000188:drug therapy; D009581:Nitrofurans / Q000627:therapeutic use*; D009617:Nocardia Infections / Q000188:drug therapy; D009821:Oils / Q000494:pharmacology*; D010619:Phenazines / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D011008:Pneumococcal Infections / Q000188:drug therapy; D051381:Rats; D013203:Staphylococcal Infections / Q000188:drug therapy; D013268:Stimulation, Chemical; D013290:Streptococcal Infections / Q000188:drug therapy; D013501:Surface-Active Agents / Q000494:pharmacology*; D013997:Time Factors; D014005:Tinea / Q000188:drug therapy; D014124:Toxoplasmosis, Animal / Q000188:drug therapy; D014352:Trypanosomiasis / Q000188:drug therapy; D014376:Tuberculosis / Q000188:drug therapy / Q000517:prevention & control
D000995:Antitubercular Agents; D009581:Nitrofurans; D009821:Oils; D010619:Phenazines; D013501:Surface-Active Agents; D002738:Chloroquine; D007538:Isoniazid